Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMNL9DS)

• Drug Name: NSD-644 Drug Info
• Synonyms: Serotonin/noradrenaline/dopamine activator (pain, depression, CNS disorder), NeuroSearch

Indication

Disease Entry	ICD 11	Status	REF
Neurological disorder	6B60	Discontinued in Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMNL9DS

Molecule-Related Drug Atlas

Drug(s) Targeting Norepinephrine transporter (NET)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[4]
Amitriptyline	DMK7F9S	Depression	6A70-6A7Z	Approved	[5]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[6]
Desipramine	DMT2FDC	Attention deficit hyperactivity disorder	6A05.Z	Approved	[4]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[7]
Bupropion	DM5PCS7	Depression	6A70-6A7Z	Approved	[8]
Tapentadol hydrochloride	DMXLSH3	Acute pain	MG31	Approved	[9]
Venlafaxine	DMR6QH0	Anxiety disorder	6B00-6B0Z	Approved	[8]
Trimipramine	DM1SC8M	Major depressive disorder	6A70.3	Approved	[10]
Duloxetine	DM9BI7M	Depression	6A70-6A7Z	Approved	[11]

Drug(s) Targeting Serotonin transporter (SERT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[4]
Amitriptyline	DMK7F9S	Depression	6A70-6A7Z	Approved	[5]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[12]
Vortioxetine	DM6F1PU	Major depressive disorder	6A70.3	Approved	[13]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[14]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[7]
Bupropion	DM5PCS7	Depression	6A70-6A7Z	Approved	[8]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[12]
Nortriptyline	DM4KDYJ	Depression	6A70-6A7Z	Approved	[12]
Trazodone	DMK1GBJ	Depression	6A70-6A7Z	Approved	[12]

Drug(s) Targeting Dopamine transporter (DAT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[7]
Dasotraline	DMLDQFV	Attention deficit hyperactivity disorder	6A05.Z	Approved	[15]
Methylphenidate	DM7SJD6	Attention deficit hyperactivity disorder	6A05.Z	Approved	[16]
Modafinil	DMYILBE	Malignant glioma	2A00.0	Approved	[12]
Phenmetrazine	DMXYTN9	Obesity	5B81	Approved	[17]
Ioflupane i-123	DMNARJT	Parkinson disease	8A00.0	Approved	[18]
DEXMETHYLPHENIDATE HYDROCHLORIDE	DM8WBAH	Attention deficit hyperactivity disorder	6A05.Z	Approved	[19]
Altropane	DMO9WDS	Attention deficit hyperactivity disorder	6A05.Z	Approved	[20]
Amitifadine	DMS1X67	Obesity	5B81	Phase 3	[21]
NAV5001	DMRSI1M	Dementia	6D80-6D86	Phase 3	[20]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine transporter (DAT)	TTVBI8W	SC6A3_HUMAN	Activator	[2]
Norepinephrine transporter (NET)	TTAWNKZ	SC6A2_HUMAN	Activator	[3]
Serotonin transporter (SERT)	TT3ROYC	SC6A4_HUMAN	Activator	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027571)
• [2] NSD-644: Phase I started.NeuroSearch A/S (CSE:NEUR), Ballerup, Denmark, GlaxoSmithKline plc (LSE:GSK; GSK), London, U.K.
• [3] Clinical pipeline report, company report or official report of Neurosearch.
• [4] Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
• [5] Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
• [6] Invivo antioxidant status: a putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):220-8.
• [7] Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
• [8] Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
• [9] 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
• [10] Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol. 2006 Oct;16(7):481-90.
• [11] Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42.
• [12] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [13] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [14] Psychopharmacological treatment of dermatological patients--when simply talking does not help. J Dtsch Dermatol Ges. 2007 Dec;5(12):1101-6.
• [15] Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults. Neuropsychopharmacology. 2015 Nov;40(12):2745-52.
• [16] Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005 Jun 1;57(11):1410-5.
• [17] Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. Eur J Pharmacol. 2002 Jun 28;447(1):51-7.
• [18] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [19] Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J Med Chem. 2007 May 31;50(11):2718-31.
• [20] Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters. Synapse. 1998 Jun;29(2):128-41.
• [21] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 927).